⚕ GalenOps field
←

SITE015-0117

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-07-14

AEs
7
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 19); relationship: not assessed

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 25); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 55); relationship: Y

severe assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-19 (study day 118); relationship: Y

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 121); relationship: N

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-27 (study day 126); relationship: N

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 131); relationship: N

Data queries

No data queries.